Peer-reviewed veterinary case report
Cabergoline treatment effects in cats with diabetes
By Scudder, Christopher J et al.·Published in Journal of feline medicine and surgery·2021·The Royal Veterinary College, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.
- Species:
- cat
Plain-English summary
A group of cats with diabetes and a condition called hypersomatotropism (which causes high levels of growth hormone) were given an oral medication called cabergoline for 90 days to see if it would help manage their diabetes better. Unfortunately, the treatment did not lead to improvements in their blood sugar control or overall quality of life. In fact, the cats needed higher doses of insulin by the end of the study. This suggests that cabergoline may not be an effective treatment for these cats.
People also search for: cat diabetes treatment · hypersomatotropism in cats · cabergoline for cats · insulin dosage for diabetic cats
Abstract
OBJECTIVES: An affordable and effective treatment is needed to manage feline hypersomatotropism. The aim of this study was to assess whether treatment with oral cabergoline for 90 days in cats with hypersomatotropism and diabetes mellitus improved diabetic and insulin-like growth factor 1 (IGF-1) control. METHODS: This was a prospective cohort non-blinded pilot study enrolling client-owned cats with spontaneously occurring diabetes mellitus and hypersomatotropism. Cats received oral cabergoline (5-10 µg/kg q24h) for 90 consecutive days. Serum IGF-1 and fructosamine concentrations were measured on days 1, 30 and 90. Quality of life was determined using the DIAQoL-pet questionnaire on days 1 and 90. RESULTS: Nine cats were enrolled and eight completed the study. There was no significant change in the following: IGF-1 (day 1 median 2001 ng/ml [range 890-2001 ng/ml]; day 30 median 2001 ng/ml [range 929-2001 ng/ml]; day 90 median 1828 ng/ml [range 1035-2001 ng/ml]; χ(2) = 0.667, = 0.805); fructosamine (day 1 median 499 µmol/l [range 330-887 µmol/l], day 30 median 551 µmol/l [range 288-722 µmol/l], day 90 median 503 [range 315-851 µmol/l]; χ(2) = 0.581, = 0.764); or DIAQoL-pet score (median on day 1 -2.79 [range -4.62 to -0.28], median on day 90 -3.24 [range -4.41 to -0.28]; = 0.715). There was a significant change of insulin dose (χ(2) = 8.667, = 0.008) with cats receiving higher insulin doses at day 90 compared with day 1 (median on day 1 was 0.98 [range 0.63-1.49] and median on day 90 was 1.56 [range 0.49-2.55] units/kg q12h; = 0.026). CONCLUSIONS AND RELEVANCE: Cabergoline did not improve diabetic control or normalise insulin-like growth factor concentration, or improve patient quality of life.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32684121/